FIELD: biotechnology; medicine.
SUBSTANCE: present invention relates to biotechnology and can be used in medicine. Invention discloses novel human amylin analogues having a number of advantages in comparison with endogenous amylin, for example, increased half-life (t1/2), as well as improved solubility and thermal stability.
EFFECT: disclosed amylin analogue polypeptides can be used in treating metabolic diseases or disorders, such as type 1 and 2 diabetes, and in providing body weight loss.
20 cl, 3 dwg, 11 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION CONTAINING INSULIN AND GLUCAGON | 2019 |
|
RU2823246C2 |
| STRUCTURES HAVING SIRP-ALPHA DOMAIN OR ITS VERSION | 2016 |
|
RU2740672C2 |
| ENGINEERED pH-DEPENDENT ANTI-CD3 ANTIBODIES, AS WELL AS METHODS FOR PRODUCTION AND USE THEREOF | 2020 |
|
RU2832079C2 |
| PEPTIDIC INTERLEUKIN-23 RECEPTOR INHIBITORS FOR ORAL ADMINISTRATION AND USE THEREOF FOR TREATING INFLAMMATORY INTESTINAL DISEASES | 2015 |
|
RU2736637C2 |
| THERAPEUTIC USE OF GLUCAGON AND ITS COMBINATION | 2019 |
|
RU2838895C2 |
| MULTI-RECEPTOR AGONIST AND MEDICAL USE THEREOF | 2020 |
|
RU2816492C2 |
| PEPTIDE ANTAGONISTS OF CALCITONIN CGRP FAMILY OF PEPTIDE HORMONES AND THEIR USE | 2017 |
|
RU2742826C2 |
| C5-BINDING POLYPEPTIDES | 2014 |
|
RU2714156C2 |
| ANTIBODIES THAT BIND TUMOR TISSUE FOR DIAGNOSIS AND TREATMENT | 2020 |
|
RU2806915C2 |
| NATRIURETIC PEPTIDE RECEPTOR-1 ANTIBODIES AND METHODS OF USE THEREOF | 2020 |
|
RU2827871C2 |
